Close Menu

NEW YORK – Thermo Fisher Scientific said this week that it anticipates reported and organic revenue growth of approximately 10 percent for the second quarter. The company had previously said that it expected Q2 organic revenues to be flat or to decline by up to 15 percent. The better-than-expected growth was primarily driven by strong global sales of PCR-based tests and other products and services related to the COVID-19 pandemic, which contributed more than $1.4 billion in revenues in the second quarter.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.